news

at a time when the pharmaceutical industry is undergoing profound changes of "de-foaming" and "comprehensive innovation", yiteng pharmaceutical has become a breath of fresh air in the industry with its steady and steady development strategy and layout of the entire industry chain. its listing prospects and ipo process are well prepared. attracted by the market. recently, as eden's listing application was accepted by the hong kong securities and futures commission, the future development path of this pharmaceutical company has become clearer, showing strong momentum to overcome the industry's cold winter.

through the introduction of new products, we not only acquired high-quality overseas resources and technologies, but also rapidly improved our production and manufacturing technology, global supply chain capabilities and key processes for complex preparations. this layout further reduces manufacturing costs, creates a healthier and more stable supply chain system, and provides strong support for its ipo.

the prospect of yiteng's listing is optimistic and the future is promising. with the continuous changes in the pharmaceutical industry and the continuous enhancement of eton pharmaceutical's own strength, its listing prospects are generally optimistic by the market. as a comprehensive pharmaceutical company that has successfully transformed, eden pharmaceutical has demonstrated significant advantages in resisting risks and industry cycles. compared with capital-oriented biotech companies, yiteng pays more attention to long-term development and stable operations, which has laid a good foundation for its performance in the capital market.

mr. ni xin, chairman and ceo of eddingpharm, said with confidence at the critical moment of ipo preparations and eddingpharm’s listing: “eddingpharm will continue to adhere to a steady and steady development strategy and rely on the advantages of the entire industry chain layout to continuously promote the research and development and commercialization process of innovative drugs. i am confident that yiteng will be listed on the market and believe that yiteng will create more value for investors with excellent performance and achieve a win-win situation for the company and investors.”

source: xianning.com